THROMBOEMBOLIC AND HAEMORRHAGIC EVENTS FOLLOWING DIRECT ORAL ANTICOAGULANTS (DOACS) DOSE ADJUSTMENT AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAF)

被引：0
|
作者：
Sun, Wen [1 ]
Tam, Tsz Kin [1 ]
Yan, Bryan P. [1 ]
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2024年 / 83卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1235-196
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [31] New oral anticoagulants for the prevention of stroke in patients with non-valvular atrial fibrillation
    Bosch, Montserrat
    Llop, Roser
    Lalueza, Pilar
    del Mar Villar, Maria
    [J]. MEDICINA CLINICA, 2013, 140 (05): : 229 - 231
  • [32] Characteristics of patients initiating oral anticoagulant therapy for management of non-valvular atrial fibrillation (NVAF)
    Masseria, C.
    Lin, I.
    Mardekian, J.
    Frean, M.
    Phatak, H.
    Kamble, S.
    Unniachan, S.
    Petkun, W.
    Abdulsattar, Y.
    Lip, G. Y. H.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1084 - 1084
  • [33] Risk of ischemic stroke associated with direct oral anticoagulants discontinuation on patients with non-valvular atrial fibrillation
    Thomsen, T. Alvaro
    Guadalupe, J. Mesa
    Huerta, C.
    de Burgos, A.
    Soriano, L. Cea
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)
  • [34] Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over
    Marie Cavillon Decaestecker
    Laurie Ferret
    Kevin Decaestecker
    Sophie Gautier
    Stéphane Verdun
    Essé Sylvestre Tsogli
    [J]. Drugs & Aging, 2021, 38 : 939 - 950
  • [35] Direct oral anticoagulants in patients with cardiac implantable devices and non-valvular atrial fibrillation: the complexity of dose adjustments and the impact on outcomes
    Santos, J. M.
    Mendes, A. R.
    Rocha, M. J.
    Goncalves, L.
    Antonio, N.
    Fortuna, A.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2020, 50 : 47 - 47
  • [36] Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over
    Decaestecker, Marie Cavillon
    Ferret, Laurie
    Decaestecker, Kevin
    Gautier, Sophie
    Verdun, Stephane
    Tsogli, Esse Sylvestre
    [J]. DRUGS & AGING, 2021, 38 (10) : 939 - 950
  • [37] Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study
    Deitelzweig, Steven
    Keshishian, Allison
    Kang, Amiee
    Jenkins, Aaron
    Atreja, Nipun
    Schuler, Patricia
    Jiang, Jenny
    Yuce, Huseyin
    Sun, Xiaoxi
    Lip, Gregory Y. H.
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 108 : 37 - 42
  • [38] Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
    Hallinen, Taru
    Soini, Erkki
    Asseburg, Christian
    Linna, Miika
    Eloranta, Pia
    Sintonen, Sari
    Kosunen, Mikko
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 745 - 755
  • [39] Direct oral anticoagulants (DOACs) use in patients with cardiac implantable devices and non-valvular atrial fibrillation: impact of off-label dose use in safety and efficacy outcomes
    Santos, Joana
    Antonio, Natalia
    Goncalves, Lino
    Rocha, Marilia J.
    Fortuna, Ana
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (06) : 1773 - 1773
  • [40] DEMOGRAPHIC AND SOCIOECONOMIC CHARACTERISTICS THAT IMPACT SELECTION OF ORAL ANTICOAGULANTS AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS
    Keshishian, A.
    Du, J.
    Xie, L.
    Yuce, H.
    Baser, O.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A55 - A55
12345